论文部分内容阅读
目的:研究DC-CIK细胞治疗对晚期肝细胞癌患者甲胎蛋白、免疫功能及循环肿瘤细胞数的影响。方法:选取2013年至2015年我院收治的26例肝细胞癌并伴有复发或转移的患者,对其治疗前后甲胎蛋白、免疫功能及循环肿瘤细胞数的数据进行分析,比较DC-CIK细胞治疗前后甲胎蛋白、循环肿瘤细胞、免疫功能的变化。根据细胞治疗次数分为1次组及>1次组,比较两组免疫功能的变化。结果:DC-CIK细胞治疗前甲胎蛋白为(603.32±155.78)ng/mL细胞回输后为(571.24±147.49)ng/mL差异无统计学意义(P>0.05)。DC-CIK细胞治疗前及细胞回输后CTC检测阳性率分别为81.8%、36.4%治疗前及回输后循环肿瘤细胞数量分别为(8.36±10.642)、(1.55±2.464),细胞治疗前后比较差异均有统计学意义(P<0.05)。细胞治疗前1天T细胞亚群CD3+、CD3~+CD4~+、CD3~+CD8~+、CD4/CD8分别为(66.05±15.31)%、(41.89±12.33)%、(23.15±8.05)%、(2.10±0.77),回输后分别为(69.69±12.91)%、(44.80±11.11)%、(23.13±7.12)%、(2.29±0.91)治疗前后比较差异无统计学意义(P>0.05)。细胞治疗次数1次组和>1次组免疫功能变化差异无统计学意义(P>0.05)。结论:DC-CIK细胞治疗可减少肝细胞癌伴复发或转移患者循环肿瘤细胞的数量,但对甲胎蛋白和免疫功能无明显影响。
Objective: To study the effect of DC-CIK cell therapy on the level of alpha-fetoprotein, immune function and circulating tumor cells in patients with advanced hepatocellular carcinoma. Methods: Twenty-six patients with hepatocellular carcinoma who had recurrent or metastatic tumors in our hospital from 2013 to 2015 were selected to analyze the data of alpha-fetoprotein, immune function and circulating tumor cells before and after treatment. The data of DC-CIK Changes of alpha-fetoprotein, circulating tumor cells and immune function before and after cell treatment. According to the number of cell therapy divided into 1 group and> 1 group, compared two groups of immune function changes. Results: There was no significant difference (571.24 ± 147.49) ng / mL between the positive cells and the positive cells (603.32 ± 155.78) ng / mL before DC-CIK cells were treated (P> 0.05). The positive rates of CTC in DC-CIK cells before and after transfusion were 81.8% and 36.4%, respectively (8.36 ± 10.642 and 1.55 ± 2.464, respectively) before and after transfusions The differences were statistically significant (P <0.05). The levels of CD3 +, CD3 ~ + CD4 ~ +, CD3 ~ + CD8 ~ + and CD4 / CD8 of the T cell subsets were (66.05 ± 15.31)%, (41.89 ± 12.33)% and (23.15 ± 8.05)% , (2.10 ± 0.77), respectively. There was no significant difference between before and after treatment (69.69 ± 12.91)%, (44.80 ± 11.11)%, (23.13 ± 7.12)% and (2.29 ± 0.91) ). There were no significant differences in the immune function between the 1st and the 1th cell treatment times (P> 0.05). Conclusion: DC-CIK cell therapy can reduce the number of circulating tumor cells in patients with hepatocellular carcinoma with recurrence or metastasis, but have no significant effect on alpha-fetoprotein and immune function.